TCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TCEB2/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis

Published:2024-09-11 Issue:1 Volume:29 Page:
ISSN:2047-783X
Container-title:European Journal of Medical Research
language:en
Short-container-title:Eur J Med Res

Author:

Deng Zhuo,Li Bin,Wang Wenzhi,Xia Wei,Zhang Lu,Chen Lihong,Jin Wen

Funder

Science and Technology Talent Support Plan of Shaanxi Provincial People's Hospital

Science and Technology Development Incubation Fund of Shaanxi Provincial People's Hospital

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40001-024-02050-9.pdf

Reference29 articles.

1. Zheng L, et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. Gynecol Oncol. 2020;159(1):239–47.

2. Yang D, et al. Global, regional, and national burden of ovarian cancer and the attributable risk factors in all 194 countries and territories during 2007–2017: a systematic analysis of the global burden of disease study 2017. J Obstet Gynaecol Res. 2021;47(12):4389–402.

3. Moufarrij S, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7.

4. Hao L, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868(1): 118878.

5. Kleih M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP